Compare Aegon Ltd. (AEG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aegon Ltd. vs GeneDx Holdings Corp — how do they compare? Aegon Ltd. trades at $8.73 (market cap $12.98B), while GeneDx Holdings Corp trades at $64.73 (market cap $1.94B). The key difference: Aegon Ltd. is far larger — about 6.7× GeneDx Holdings Corp's market cap, and Aegon Ltd. pays a 5.3% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| AEG | WGS | |
|---|---|---|
Market Cap | $12.98B | $1.94B |
Sector | Financials | Technology |
52-Week High | $8.79 | $167.51 |
52-Week Low | $6.79 | $34.51 |
Enterprise Value | $14.11B | $1.94B |
Dividend Yield | 5.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $8.75, up 1.04% on the day, with a P/E of 12.86 and P/S of 0.55 indicating potential undervaluation. Recent earnings show mixed results, beating estimates in Q2 and Q3 2025 but missing in Q4. The company is undergoing strategic simplification, including moving its legal seat to Delaware and focusing on U.S. operations, supported by a dividend of $0.25 payable in July 2026. Technical indicators are bullish on moving averages but neutral on oscillators.
Outlook is cautiously optimistic with a 27.78% analyst buy rating, driven by restructuring benefits and U.S. market focus. Risks include execution challenges in the transition, volatile cash flows, and competitive pressures. The stock presents a value opportunity if the strategic pivot succeeds, but investors should monitor earnings consistency and debt management.
GeneDx Holdings Corp. (WGS) trades at $68.89, up 2.04% today, with a bullish technical signal from moving averages and a consensus analyst price target of $75.40. Despite recent earnings beats in Q3 and Q4 2025, the company reported a net loss of -$21.02M in 2025, with profitability metrics like ROE at -30.42% reflecting operational challenges. The stock faces headwinds from a securities class action lawsuit alleging fraud, as noted in multiple legal alerts from July 2026.
The outlook is mixed: strong analyst buy ratings (90.91%) suggest upside potential, but negative margins and legal risks pose significant threats. Investors should weigh the high valuation multiples, such as EV/EBITDA of 161.17, against growth prospects in the genomics sector, with cash flow trends showing volatility into 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
